The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...

Vertex Pharmaceuticals has been treading water for the past six months, recording a small loss of 1.6% while holding steady ...

The fresh FDA approval allows the use of the cell therapy in patients as young as two years old with sickle cell disease (SCD ...

VRTX operates within healthcare sector of S&P 500, as CASGEVY expansion highlights evolving genetic medicine and rare disease ...

Vertex Pharmaceuticals (NASDAQ:VRTX) is set to release its earnings on Monday, May 5, 2025. For those trading based on events, analyzing historical stock behavior around earnings announcements can be ...

Members of Congress have traded $VRTX stock 4 times in the past 6 months. Of those trades, 2 have been purchases and 2 have been sales. Here’s a breakdown of recent ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Vertex ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) will report its first-quarter earnings on Monday. As the company reports after market hours, Wall Street expects $4.32 in EPS and $2.85 billion in revenues.

Looking ahead to 2030, our model projects VRTX could trade at an average price of $890.37, with a potential range between $667.77 and $1,112.96. This represents a potential 77.9% return from today's ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our Multi-Factor Investor model based on the published ...